- Pressemitteilung BoxID 502525
Ypsomed launches new commercial product mylife(TM) DailyDose(TM)
The credit-card sized self-injection system consists of three small syringes, which are pre-fillable with the diabetic's daily insulin requirement. Mylife(TM) DailyDose(TM) can be tucked away comfortably and discretely and used as needed. The transparent case makes it possible to tell at a glance, which dose was already administered.
"Be it sport, travelling or going out - for diabetics it is not always prac-tical to carry traditional injection or infusion systems. With mylife(TM) DailyDose(TM) a reliable solution is always at hand, which outperforms existing alternatives with regard to practicability and costs. We are delighted to have mylife(TM) DailyDose(TM) in our mylife(TM) product range", explains Simon Michel, member of the executive board of the Yp-somed group.
The distribution contract with the Swedish manufacturer Insulution AB was sealed last week. Ypsomed will bring mylife(TM) DailyDose(TM) to the market in Switzerland, Germany, Great Britain, Norway, Austria and the Netherlands and other countries will be considered in the future.
Über Ypsomed AG
The Ypsomed Group is a leading, independent developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with over 25 years of experience. Originated in 2003 from the famous company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disturbances, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and tech-nology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife(TM) Diabetescare and YDS(TM) Ypsomed Delivery Systems in retail-ing and in business-to-business trading. Under the brand name mylife(TM) Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for treatment of diabetes. The range from YDS(TM) reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product line of pen systems and autoinjectors, which can be adapted to customer requirements, contract production in the development and production sectors as well as the assembly of injection systems with medications Ypsomed thus offers demand-orientated product and service solutions to pharmaceutical and biotech companies worldwide.
Ypsomed has its headquarters in Burgdorf. It disposes of several production sites in Switzerland and in the Czech Republic, of subsidiaries throughout Europe as well as leading, independent marketing partners throughout the world. The Ypsomed group has around 1,050 employees.
Diese Pressemitteilungen könnten Sie auch interessieren
Heraeus Kulzer macht es Zahntechnikern noch einfacher, sich fachlich auf dem neusten Stand zu halten. Die neue Kurs-Website unter www.heraeus-kulzer.com/kursprogramm...
"Werkzeugtechnologien für die Medizintechnik" sind das Schwerpunktthema des nächsten Treffens des Arbeitskreis Werkzeug- und Formenbau. Am 13. Juni 2013 tagt das...
Heilmittel einfach über das Internet abrechnen. Für alle Leistungserbringer im Bereich Heilmittel stellt das Deutsche Medizinrechenzentrum (DMRZ) im Mai auf gleich...